The research, published in the journal Nature Communications, sheds new light on the surprising resilience of the brain during the asymptomatic period of Parkinson’s.
In their study, a team led by Universite de Montreal neuroscientist Louis-Eric Trudeau demonstrated that movement circuits in the brains of mice are insensitive to an almost total loss of active secretion of this chemical messenger.
This observation is surprising because dopamine is a chemical messenger recognised for its importance in movement. And in Parkinson’s disease, dopamine levels in the brain drop inexorably.
“This observation went against our initial hypothesis, but that’s often the way it is in science, and it forced us to re-evaluate our certainties about what dopamine really does in the brain,” said Trudeau, a professor at the varsity’s Department of Pharmacology and Physiology and Department of Neurosciences.
Using genetic manipulations, the team eliminated the ability of dopamine-producing neurons to release this chemical messenger in response to the normal electrical activity of these cells.
They expected to see a loss of motor function in these mice similar to what is seen in individuals with Parkinson’s. But surprisingly, the mice showed a completely normal capacity for movement.
Meanwhile, measurements of overall dopamine levels in the brain revealed that extracellular levels of dopamine in the brain of these mice were normal.
These results suggest that the activity of movement circuits in the brain requires only low basal levels of dopamine.
It is therefore likely that in the early stages of Parkinson’s disease, basal dopamine levels in the brain remain sufficiently high for many years — this, despite the gradual loss of dopamine-producing neurons. It is only when a minimum threshold is exceeded that motor perturbations appear.
According to the scientists, by identifying the mechanisms involved in the secretion of dopamine in the brain, this advance in Parkinson’s research could help to identify new approaches to reduce the symptoms of this incurable neurodegenerative disease.
–IANS
rvt/svn